Currently, there are 1.29B common shares owned by the public and among those 1.26B shares have been available to trade.
Insiders at the company have transacted a total of 34 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 18 of these insider trades were purchases, accounting for 111,104 shares. Insider sales of the common stock occurred on 16 occasions, with total insider shares sold totaling 261,891 shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The company’s stock has a 5-day price change of -1.27% and 11.81% over the past three months. CVS shares are trading -3.36% year to date (YTD), with the 12-month market performance down to -13.25% lower. It has a 12-month low price of $64.41 and touched a high of $88.75 over the same period. CVS has an average intraday trading volume of 10.89 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 2.12%, 0.11%, and 6.68% respectively.
Institutional ownership of CVS Health Corp (NYSE: CVS) shares accounts for 82.25% of the company’s 1.29B shares outstanding.
It has a market capitalization of $96.03B and a beta (3y monthly) value of 0.51. The stock’s trailing 12-month PE ratio is 11.80, while the earnings-per-share (ttm) stands at $6.47. The company has a PEG of 3.19 and a Quick Ratio of 0.63 with the debt-to-equity ratio at 1.04. Price movements for the stock have been influenced by the stock’s volatility, which stands at 1.98% over the week and 2.08% over the month.
Analysts forecast that CVS Health Corp (CVS) will achieve an EPS of $CVS Health Corporation for the current quarter, $76.31 for the next quarter and $Stocks for Type. The lowest estimate earnings-per-share for the quarter is $Cel-Sci Corporation while analysts give the company a high EPS estimate of $Las Vegas Sands Corp.. Comparatively, EPS for the current quarter was $Novartis AG a year ago. Earnings per share for the fiscal year are expected to decrease by -4.62%, and 10.96% over the next financial year.
Looking at the support for the CVS, a number of firms have released research notes about the stock. HSBC Securities stated their Buy rating for the stock in a research note on December 22, 2023, with the firm’s price target at $94. Evercore ISI coverage for the CVS Health Corp (CVS) stock in a research note released on September 19, 2023 offered a Outperform rating with a price target of $83. Piper Sandler on their part issued Overweight rating on May 26, 2023.
